Screening for Prostate Cancer with Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion Academic Article uri icon

Overview

MeSH Major

  • Early Detection of Cancer
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • In one randomized trial, PSA testing in men who would not otherwise have been screened resulted in reduced death rates from prostate cancer, but it is uncertain whether the size of the effect was worth the harms associated with screening and subsequent unnecessary treatment. Although there are limitations to the existing data, there is evidence to suggest that men with longer life expectancy may benefit from PSA testing. Adverse events associated with prostate biopsy are low for the majority of men; however, several population-based studies have shown increasing rates of infectious complications after prostate biopsy, which is a concern.

publication date

  • August 20, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3776923

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.43.3441

PubMed ID

  • 22802323

Additional Document Info

start page

  • 3020

end page

  • 5

volume

  • 30

number

  • 24